Followers | 46 |
Posts | 4493 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 05, 2020 6:20:17 PM
By Carol E. Lee, Kristen Welker and Elyse Perlmutter-Gumbiner
WASHINGTON — There are 14 potential coronavirus vaccines under development as part of President Donald Trump's administration's program to fast-track one for use as early as January, senior administration officials tell NBC News.
That number was whittled down several weeks ago from 93 vaccines in development that were studied as part of the program, known as “Operation Warp Speed,” officials said.
Over the next two weeks, the 14 remaining vaccines will undergo additional testing and officials expect that anywhere from six to eight of them will make it to a subsequent round of clinical trials. Ultimately, the officials said, the goal is to have three or four vaccines make it through final testing and cleared for use early next year.
https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326
Recent ALT News
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Altimmune to Participate at Leerink Partners Therapeutics Forum • GlobeNewswire Inc. • 07/02/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/23/2024 05:45:00 PM
- Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 08:45:00 PM
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/17/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/10/2024 09:45:00 AM
- Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/29/2024 11:31:00 AM
- Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 05/29/2024 09:45:00 AM
- Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) • PR Newswire (US) • 05/21/2024 01:00:00 PM
- The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT • PR Newswire (US) • 05/21/2024 09:45:00 AM
- Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) • PR Newswire (US) • 05/14/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm • PR Newswire (US) • 05/09/2024 09:51:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:04:51 AM
- Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM